{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:56:43Z","timestamp":1777593403987,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Health and Family Planning Commission of China","award":["201402014"],"award-info":[{"award-number":["201402014"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai","doi-asserted-by":"publisher","award":["17DZ2260100"],"award-info":[{"award-number":["17DZ2260100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570884"],"award-info":[{"award-number":["81570884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770961"],"award-info":[{"award-number":["81770961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SMC-ChenXing Yong Scholar Program","award":["2016, Class A"],"award-info":[{"award-number":["2016, Class A"]}]},{"name":"Shanghai Municipal Education Commission-Gaofeng Clinical Medicine","award":["20152223"],"award-info":[{"award-number":["20152223"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.exer.2018.03.030","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T06:14:13Z","timestamp":1523340853000},"page":"51-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Characterization of a conjunctival melanoma cell line CM-AS16, newly-established from a metastatic Han Chinese patient"],"prefix":"10.1016","volume":"173","author":[{"given":"Yongyun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-3820","authenticated-orcid":false,"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianqun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renbing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2018.03.030_bib1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ijc.2910540513","article-title":"Establishment and characterization of human ocular melanoma cell lines","volume":"54","author":"Aubert","year":"1993","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.exer.2018.03.030_bib2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/bjc.2017.10","article-title":"A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor","volume":"116","author":"Bendell","year":"2017","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.exer.2018.03.030_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.semdp.2013.11.002","article-title":"Molecular pathology of melanocytic tumors","volume":"30","author":"Busam","year":"2013","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.exer.2018.03.030_bib4","doi-asserted-by":"crossref","first-page":"58021","DOI":"10.18632\/oncotarget.10770","article-title":"Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exer.2018.03.030_bib5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The american college of surgeons commission on cancer and the american cancer society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.exer.2018.03.030_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma","volume":"15","author":"Clark","year":"1984","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.exer.2018.03.030_bib7","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib8","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1167\/iovs.14-15239","article-title":"A murine model for metastatic conjunctival melanoma","volume":"56","author":"de Waard","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.03.030_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14740338.2015.1011618","article-title":"BRAF and MEK inhibition in melanoma","volume":"14","author":"Dossett","year":"2015","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.exer.2018.03.030_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.exer.2018.03.030_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjd.12504","article-title":"The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort","volume":"169","author":"Ekedahl","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.exer.2018.03.030_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/dc.22948","article-title":"Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma","volume":"41","author":"Erdag","year":"2013","journal-title":"Diagn. Cytopathol."},{"key":"10.1016\/j.exer.2018.03.030_bib14","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1167\/iovs.04-0093","article-title":"BRAF mutations in conjunctival melanoma","volume":"45","author":"Gear","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.03.030_bib15","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.exer.2018.03.030_bib16","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00008390-200008000-00006","article-title":"Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45","volume":"10","author":"Heegaard","year":"2000","journal-title":"Melanoma Res."},{"key":"10.1016\/j.exer.2018.03.030_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ajo.2007.10.022","article-title":"Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas","volume":"145","author":"Hu","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib19","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.exer.2018.03.030_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Canc. Immunol. Res."},{"key":"10.1016\/j.exer.2018.03.030_bib21","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/bjo.2006.110841","article-title":"A new cell line from a recurrent conjunctival melanoma","volume":"91","author":"Keijser","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib22","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/cncr.30463","article-title":"Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.exer.2018.03.030_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib24","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1167\/iovs.10-6934","article-title":"Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes","volume":"52","author":"Lake","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.03.030_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/aos.13007","article-title":"BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaophthalmol.2015.3200","article-title":"A retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with BRAF mutations","volume":"133","author":"Larsen","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.exer.2018.03.030_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11626-997-0021-6","article-title":"Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes","volume":"33","author":"Le Poole","year":"1997","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.exer.2018.03.030_bib28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.exer.2018.03.030_bib29","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2015.329","article-title":"Stamping out RAF and MEK1\/2 to inhibit the ERK1\/2 pathway: an emerging threat to anticancer therapy","volume":"35","author":"Mandal","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.exer.2018.03.030_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000452473","article-title":"Systemic BRAF\/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma","volume":"3","author":"Mor","year":"2017","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.exer.2018.03.030_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.exer.2005.04.018","article-title":"Establishment of two cell lines derived from conjunctival melanomas","volume":"81","author":"Nareyeck","year":"2005","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.03.030_bib32","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.exer.2018.03.030_bib33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00280-016-2993-y","article-title":"Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma","volume":"77","author":"Ouellet","year":"2016","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.exer.2018.03.030_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/bjo.78.7.520","article-title":"Orbital exenteration in 95 cases of primary conjunctival malignant melanoma","volume":"78","author":"Paridaens","year":"1994","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjd.13069","article-title":"Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma","volume":"171","author":"Pozzobon","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.exer.2018.03.030_bib37","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.exer.2018.03.030_bib38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jcp.21246","article-title":"Mitogenic signaling pathways induced by G protein-coupled receptors","volume":"213","author":"Rozengurt","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.exer.2018.03.030_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/56.3.489","article-title":"Melanomas of the eye and other noncutaneous sites: epidemiologic aspects","volume":"56","author":"Scotto","year":"1976","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.exer.2018.03.030_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0039-6257(97)00122-7","article-title":"Conjunctival melanoma","volume":"42","author":"Seregard","year":"1998","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib41","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/bjophthalmol-2014-305730","article-title":"Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients","volume":"99","author":"Sheng","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.exer.2018.03.030_bib43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/archopht.118.11.1497","article-title":"Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.03.030_bib44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/01.MLG.0000157327.10597.86","article-title":"Conjunctival melanoma: the role of conservative surgery and radiotherapy in regional metastatic disease","volume":"115","author":"Tatla","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.exer.2018.03.030_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/10590500500234970","article-title":"Human melanocyte biology, toxicology, and pathology","volume":"23","author":"Tolleson","year":"2005","journal-title":"J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev."},{"key":"10.1016\/j.exer.2018.03.030_bib47","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ophtha.2003.11.001","article-title":"Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy","volume":"111","author":"Tuomaala","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.03.030_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu438.43","article-title":"LBA35overall survival and biomarker results from a phase 2 study of MEK1\/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS-mutant melanoma","volume":"25","author":"van Herpen","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.exer.2018.03.030_bib49","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.2014.59","article-title":"Comparison of MelanA\/MART-1 and HMB45 labeling in desmoplastic melanoma","volume":"27","author":"Weissinger","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.exer.2018.03.030_bib50","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1167\/iovs.17-22376","article-title":"Conjunctival melanoma in Chinese patients: local recurrence, metastasis, mortality, and comparisons with caucasian patients","volume":"58","author":"Zhou","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448351830054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448351830054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:33:53Z","timestamp":1720215233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448351830054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":50,"alternative-id":["S001448351830054X"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2018.03.030","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of a conjunctival melanoma cell line CM-AS16, newly-established from a metastatic Han Chinese patient","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2018.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}